QSS
AVTX icon

Quantitative Systematic Strategies’s Avalo Therapeutics AVTX Stock Holding History

Quantitative Systematic Strategies’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-16
Closed -$150K – 44
2021
Q2 		$150K Sell
16
-11
-41% -$92.1K 0.05% 430
2021
Q1 		$232K Buy
+27
New +$255K 0.04% 528

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Quantitative Systematic Strategies's AVTX Position: Q3 2021 in Review

Quantitative Systematic Strategies sold out of Avalo Therapeutics (AVTX) in Q3 2021, closing a stake of 16 shares — an estimated $150K sold.

Quantitative Systematic Strategies first reported a position in AVTX in Q1 2021 and held it in 2 quarters. The position peaked at $232K in Q1 2021. 71 funds tracked by Wall St. Rank hold AVTX as of Q3 2021.

  • Quantitative Systematic Strategies reported no remaining Avalo Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Quantitative Systematic Strategies sold 16 Avalo Therapeutics shares in Q3 2021, an estimated $150K.
  • Quantitative Systematic Strategies first reported a position in Avalo Therapeutics in Q1 2021 and held it in 2 quarters.
  • Quantitative Systematic Strategies's Avalo Therapeutics position peaked at $232K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2021.

Based on Quantitative Systematic Strategies's 13F filing for Q3 2021, filed 16 Nov 2021.